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A B S T R A C T
Familial cortical myoclonic tremor with epilepsy (FCMTE) is an autosomal dominant epilepsy syndrome
with considerable clinical and genetic heterogeneity. The most important clinical manifestations include
adult onset, cortical myoclonic tremor, with or without epileptic seizures. Of the four loci reported,
which included 8q24 (FCMTE1), 2p11.1-q12.2 (FCMTE2), 5p15.31-p15.1 (FCMTE3), and 3q26.32-3q28
(FCMTE4), only one probably causative mutation was found co-segregated in two FCMTE2 pedigrees in
the a2-adrenergic receptor subtype B (ADRA2B) gene. In this review we discuss studies that focused on
the molecular genetics of FCMTE, its neuropathology, clinical, neurophysiological and neuroimaging
features, which may offer useful clues for the search for causative FCMTE genes. Next-generation
sequencing has identiﬁed many causative genes in monogenic diseases. However, most next-generation
sequencing applications focus on detecting single nucleotide variants or small insertions/deletions,
which do not completely resolve the challenge of identifying causative genes in FCMTE. Recent progress
in exploring FCMTE has revealed that special mutations such as copy number variants, exon
rearrangements and large trinucleotide repeat expansion (or polynucleotide repeat expansion) should
be considered. Clues from neuropathological, clinical, neurophysiological and neuroimaging studies
indicate that the candidate causative genes should be expressed in the cerebellum, especially in Purkinje
cells, and be associated with calcium signaling and GABA receptors. We propose that the developing
novel algorithms of next-generation sequencing data, which could detect structure variants and
candidate causative gene selection when combined with special mutations detection analysis represent
possible future direction of a rational search for causative genes in FCMTE.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Familial cortical myoclonic tremor with epilepsy (FCMTE), which
is widely known as benign adult familial myoclonic epilepsy
(BAFME) in Japan, and autosomal dominant cortical myoclonus and
epilepsy (ADCME) in Europe, was ﬁrst reported in the 1980s in the
Japanese population with an autosomal dominant condition [1,2].
FCMTE is also described under many other terms including
familial adult myoclonic epilepsy (FAME), familial cortical
myoclonic tremor (FCMT), familial cortical tremor with epilepsy
(FCTE), familial essential myoclonus and epilepsy (FEME), familial* Corresponding author. Tel.: +86 571 87783777; fax: +86 571 87784556.
E-mail address: luoweirock@126.com (W. Luo).
1 These authors contributed equally to this work and should be considered co-
ﬁrst authors.
http://dx.doi.org/10.1016/j.seizure.2015.12.004
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights rebenign myoclonus epilepsy of adult onset (FMEA) and here-
dofamilial tremor and epilepsy (HTE).
The most important clinical manifestations include adult onset,
cortical myoclonic tremor (CMT), with or without epileptic
seizures that mainly manifest as generalized tonic-clonic seizures
(GTCS). CMT is usually the ﬁrst symptom (mean age at onset is
35 years, range 10–60 years), and is characterized by tremulous
ﬁnger movements and myoclonus of the extremities, which are
increased by action and posture [2].
Electromyography (EMG) can detect giant somatosensory
evoked potential (g-SEP) and long-latency cortical reﬂex (C-reﬂex)
in affected members, which collectively support the cortical origin
of CMT [2]. Most antiepileptic drugs, especially clonazepam and
valproic acid were reported to improve both CMT and GTCS.
However, a potentially severe and life-threatening situation was
reported in FCMTE patients with use of gabapentin [3]. Based on
clinical and electrophysiological grounds, van Rootselaar et al.served.
Z.-d. Cen et al. / Seizure 34 (2016) 83–8984proposed that BAFME, ADCME, FAME, FCMT, FCTE, FEME, FMEA,
and HTE should be regarded as integral components of one disease
spectrum named as FCMTE and a diagnostic criterion for FCMTE
was subsequently proposed [2]. With the identiﬁed clinical and
electrophysiological features, FCMTE is a well-deﬁned epilepsy
syndrome that still awaits nosological placement in the Interna-
tional League Against Epilepsy (ILAE) classiﬁcation [4].
Four loci were identiﬁed including 8q24 (FCMTE1), 2p11.1-
q12.2 (FCMTE2), 5p15.31-p15.1 (FCMTE3) and 3q26.32-3q28
(FCMTE4), and several possibly/probably causative genes were
also reported (see Tables 1 and 2). However, a signiﬁcant gap
remains between the real causative genes and FCMTE [5–21].
Herein, we have reviewed previous molecular genetic studies of
FCMTE and associated advances in neuropathological, clinical,
neurophysiological and neuroimaging studies. We aim to provide
possible explanations for the difﬁculties of previous studies to
identify causative genes of FCMTE, and to offer future directions for
the search for causative genes of FCMTE.
1.1. Recent advances in the identiﬁcation of causative gene region
FCMTE pedigrees were previously reported in Japan, Italy,
France, Thailand, Spain and China with considerable genetic
heterogeneity. Great effort has been made recently, and four loci
including 8q24 (FCMTE1), 2p11.1-q12.2 (FCMTE2), 5p15.31-p15.1
(FCMTE3) and 3q26.32-3q28 (FCMTE4) have been identiﬁed (see
Table 1) [5–22].
FCMTE1 (OMIM 601068) was the ﬁrst locus that identiﬁed in a
large pedigree (i.e., FCMTE1 No.1), and four small pedigrees (i.e.,
FCMTE1 No.2–5) from Japan. Plaster et al. localized four small
pedigrees (i.e., FCMTE1 No.2–5) to a relatively small region (i.e., a
4.6 cM interval from D8S514 to D8S1804) in 1999 [6]. However, we
noticed that in the ﬁve microsatellite markers (i.e., D8S514,
D8S1826, 572-18, D8S384 and D8S1804) they chose for haplotype
analysis, the physical positions of D8S384, D8S514 and D8S1826
should be chr8: 118456019–118456384, chr8: 123742103–
123742461 and chr8: 123856163–123856442. The position of
microsatellite markers above were mixed in an incorrect array due
to limited information at that time. Herein, we have analyzed their
haplotype and identiﬁed that the downstream boundary of
causative gene region was D8S514. The large pedigree of FCMTE1Table 1
Reported loci and their pedigrees of FCMTE.
Clinical type
OMIM No.
Reference Origin/Pedigree No. Causative gene re
FCMTE1 [5] JPN/No.1 8q23.3-q24.11 
OMIM 601068 [6] JPN/No.2-5 8q24.13 
[7] JPN/No.1 8q24.11-q24.13 
[8] CHN/No.6 8q22.3-q24.13 
FCMTE2 [9] ITA/No.1 2p11.1-q12.2 
OMIM 607876 [10] ITA/No.2,3 2p11.1-q12.2 
[11,12] ITA/No.4,5 2p11.1-q12.2 
[13] ITA/No.6 2p11.1-q12.2 
[14] SPA/No.7 2p11.1-q12.2 
[15] ITA/No.8 2p11.1-q12.2 
[16] AUS&NZL/No.9 2p11.1-q12.2 
[17] ITA/No.10 2p11.1-q12.2 
[18] ITA/No.1,11 2p11.1-q12.2 
FCMTE3 [19] FRA/No.1 5p15.31-p15 
OMIM 613608 [20] CHN/No.2 5p15.31-p15.1 
FCMTE4OMIM 615127 [21] THA/No.1 3q26.32-q28 
JPN, Japan; ITA, Italy; SPA, Spain; AUS, Australia; NZL, New Zealand; FRA, France; CH
deletions; SS, Sanger sequencing; E-Rs, Exon rearrangements; MLPA, multiplex ligation(i.e., FCMTE1 No.1) was ﬁrstly localized to an 8 cM interval
(i.e., between D8S1784 and D8S1694) by Mikami et al. in 1999
[5]. Mori et al. remapped the causative gene region to a 7.16 Mb
interval (i.e., between rs1898287 and rs2891799) in FCMTE1 No.1
pedigree. Sanger sequencing and copy number variants (CNVs)
analysis failed to identify any causative mutation in this 7.16 Mb
interval in FCMTE1 No.1 pedigree [7]. Recently, Cen et al. reported
a Chinese FCMTE1 pedigree (i.e., FCMTE1 No.6), which was also
localized on 8q22.3-q24.13. Whole-exome sequencing (WES) was
performed and a single nucleotide variant (SNV) in the SLC30A8
gene was co-segregated in the pedigree. However, evidence
supporting the SLC30A8 gene as the causative gene of FCMTE1 was
insufﬁcient [8].
FCMTE2 (OMIM 607876) was the most widely reported type of
FCMTE and most of the FCMTE2 pedigrees came from European
countries (i.e., FCMTE2 No.1-11). Licchetta et al. narrowed the
causative gene region to a 10.4 Mb interval (i.e., between D2S181
and D2S2311) by reviewing previous reports of the localization of
FCMTE2 pedigrees [17]. Dozens of candidate genes in FCMTE2
locus have been screened and only one probably causative
mutation in the ADRA2B gene was co-segregated in two pedigrees
(i.e., FCMTE2 No.1 and No.11), which shared a common ancestor
[18]. No SNVs, small insertions/deletions (indels), or large indels in
the ADRA2B gene was detected in the other two FCMTE2 pedigrees
(i.e., FCMTE2 No.4 and No.6) [18]. Until now, no other mutation in
ADRA2B has been reported in other FCMTE pedigrees. These
indicate that additional evidence is needed to conﬁrm whether or
not ADRA2B is the authentic causative gene in FCMTE2 locus, while
the search for a second causative gene in this locus is still formally
possible.
FCMTE3 (OMIM 613608) was reported in a French pedigree (i.e.,
FCMTE3 No.1) and a Chinese pedigree (i.e., FCMTE3 No.2)
[19,20,22]. Sanger sequencing of two candidate genes (SEMA5A
and CTNND2) in FCMTE3 No.1 pedigree did not detect any
causative mutation [18]. FCMTE4 (OMIM 615127) was only
reported in a Thai pedigree (i.e., FCMTE4 No.1) without causative
gene identiﬁed [21].
Although next-generation sequencing (NGS) like WES and
whole-genome sequencing (WGS) can detect the causative
mutation without causative gene regional information, localiza-
tion of causative gene remains very important in causative genegion Gene
Unknown
Coding region of ‘‘Kv8.1’’ gene excluded
SNVs and SIDs in all exons of 38 genes in this region excluded by SS
One SNV in SLC30A8 by NGS
Unknown
Unknown
Unknown
Unknown
SNVs and SIDs of SIAT9, KCNIP3, REEP1, VAMP5 and DRD5P1 excluded
by SS.E-Rs of REEP1 and DRD5P1 excluded by MLPA
Unknown
Unknown
Unknown
One SID in ADRA2B detected in No.1 and No.11 pedigrees by NGS and
SS. No SNVs, SIDs or large indels of ADRA2B was detected in No.4 and
No.6 pedigrees.
SNVs and SIDs of SEMA5A and CTNND2 were excluded by SS
Unknown
Unknown
N, China; THA, Thailand; SNVs, single nucleotide variants; SIDs, small insertions/
 dependent probe ampliﬁcation; NGS, next-generation sequencing.
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Z.-d. Cen et al. / Seizure 34 (2016) 83–89 85identiﬁcation, especially when NGS fails to detect the causative
mutation. With increasing numbers of FCMTE pedigrees being
mapped, narrowing of the reported causative gene regions should
be helpful for identiﬁcation of the causative genes.
1.2. Recent advances in possibly/probably causative genes of FCMTE
and similar phenotypes
Recently, some possibly/probably causative genes of FCMTE and
similar phenotypes have been reported (see Table 2) [18,23–26].
In 2012, Kato et al. reported a rare missense mutation
c.5720G>A (p.Arg1907His) of the UBR5 (i.e., ubiquitin protein
ligase E3 component n-recognin 5, 8q22.3) gene in a Japanese
FCMTE pedigree without localization analysis [23]. Mutations in
the genes encoding E3 ubiquitin-protein ligases were associated
with hereditary neurological diseases including Angelman syn-
drome and autosomal recessive juvenile Parkinsonism, which
provided evidence that a rare mutation in UBR5 could be associated
with FCMTE [23].
In 2012, Russell et al. reported a Canadian pedigree with
familial cortical myoclonic (FCM), which is characterized by
autosomal dominant, adult onset and cortical myoclonus
without associated seizures. Additionally, EMG detected g-SEP
in some affected members. Combining linkage analysis and WES,
a rare missense mutation c.61G>C (p.Glu21Gln) in the NOL3 (i.e.,
nucleolar protein 3, 16q22.1) gene that encodes nucleolar
protein 3 was co-segregated in the pedigree. The c.61G>C
mutation alters post-translational modiﬁcation of nucleolar
protein 3 in cells. However, NOL3 knockout mice did not exhibit
any overt motor phenotype, including myoclonus and SEP was
statistically equivalent when comparing NOL3 knockouts and
WT mice [24].
In 2013, Stogmann et al. reported a consanguineous Egyptian
pedigree with autosomal recessive cortical myoclonic tremor and
epilepsy. All ﬁve affected members in the pedigree experienced
GTCS and presented with CMT in adolescence. Combining linkage
analysis and WES, they identiﬁed a rare frameshift mutation
c.503delG (p.Trp168CysfsX163) of the CNTN2 (i.e., contactin 2,
1q32.1) gene, which co-segregated in the pedigree [25]. CNTN2-
deﬁcient mice showed spontaneous epileptic seizures and
increased seizure susceptibility to convulsive stimuli [27]. This
observation highly supported the role of the CNTN2 gene as the
underlying causative gene in this pedigree and phenotype.
In 2013, Marti-Masso et al. detected a rare nonsense mutation
c.77G>A (p.Trp26X) by WES in the ACMSD (i.e., a-amino-b-
carboxymuconate-e-semialdehyde decarboxylase, 2q21.3) gene,
which co-segregated in a Spanish FCMTE pedigree [26]. ACMSD is a
component of the kynurenine pathway, which has already been
identiﬁed in the genesis of epileptic seizures [28,29].
In 2014, De Fusco et al. detected a rare in-frame insertion/
deletion in the ADRA2B gene (coding protein a2-adrenergic
receptor subtype B, a2B-AR) by WES and target capturing
sequencing in two affected members from a pedigree (i.e., FCMTE2
No.1) localized on 2p11.1-q12.2. They also detected the same
mutation in a second pedigree (i.e., FCMTE2 No.11), which
demonstrated a common ancestor with the FCMTE2 No.1 pedigree
by haplotype analysis [18]. The mutant a2B-AR cannot form a
stable complex with spinophilin, which would result in a lack of
spinophilin regulation on responses that were mediated by the
mutant a2B-AR. It also signiﬁcantly increases the intensity of
receptor-mediated Ca2+ signaling [18]. Although functional studies
supported this gene as the causative gene of FCMTE2, De Fusco
et al. could not detect any other mutation in the ADRA2B gene in the
other two pedigrees (i.e., FCMTE2 No.4 and No.6) that localized on
2p11.1-q12.2. De Fusco et al. explained that they could be two
distinct clinical entities and suggested that further research might
Z.-d. Cen et al. / Seizure 34 (2016) 83–8986identify another causative gene in FCMTE2 locus in the FCMTE2
No.4 and No.6 pedigrees [18].
In 2015, Cen et al. detected a rare missense mutation
c.206A>T (p.Tyr69Phe) of the SLC30A8 gene in a Chinese FCMTE1
pedigree (i.e., FCMTE1 No.6). However, the evidence supporting
this gene as the causative gene of FCMTE1 is insufﬁcient in the
bioinformatics analysis. No critical mutation was detected in the
remaining three Chinese FCMTE pedigrees by Sanger sequencing
[8].
Several possibly/probably FCMTE genes were reported when
using WES. However, none of the genes had sufﬁcient evidence to
guarantee their association with FCMTE. Those reports all could
not detect different mutations of the possibly/probably causative
genes in multiple independent pedigrees with the same or similar
phenotypes and no other research group has yet conﬁrmed these
results [30].
1.3. Recent advances in related studies offered clues for candidate
gene selection
Although six possibly/probably FCMTE and similar phenotype-
associated genes have been reported, ADRA2B was the only
probably causative gene in the previously reported FCMTE locus
(FCMTE2) [18]. Causative genes in FCMTE1, FCMTE3 and FCMTE4,
and even some FCMTE2 pedigrees (i.e., FCMTE2 No.4 and No.6)
remain unknown. This indicates that NGS is insufﬁcient to resolve
the challenge of identifying causative genes in FCMTE. Recently,
some neuropathological, clinical, neurophysiological and neuro-
imaging studies of FCMTE were reported, which may offer useful
information for candidate gene selection and clues for further
study (see Fig. 1).
1.4. Updated studies on neuropathology
In 2004, 2007 and 2012, van Rootselaar et al. reported the
pathological results of three FCMTE patients from a DutchFig. 1. Neuropathological, clinical, neurophysiological and neuroimaging studies of FCM
FCMTE. Frames before the arrows summarized neuropathological, clinical, neurophysiolo
shared features with SCAs, and other CM, and possible pathophysiology of FCMTE like
Purkinje cells; CM, cortical myoclonus; SICI, short-interval intracortical inhibition; DBNpedigree, all of which showed marked loss and morphological
changes (i.e., somal sprouting and loss of the dendritic tree) of
Purkinje cells in the cerebellar cortex with no or limited changes in
the sensorimotor cortex [31–33]. Another post-mortem neuro-
pathological study of an FCMTE patient from a South African
pedigree also showed Purkinje cells loss, dentate atrophy and
neuronal cell loss, with gliosis in the olives and pallidum
[34]. These neuropathological studies indicated that the cerebel-
lum was involved in the pathophysiology of FCMTE, which
showed remarkable similarities to changes that were described in
SCA6, a pure cerebellar syndrome caused by a CACNA1A mutation
[35]. In addition, Purkinje cells dysfunction and loss were the
major pathophysiological changes seen in some other spinocer-
ebellar ataxias (SCAs) (i.e., SCA1, 2, 3, 5, 14, 15 and 16), and
deranged calcium signaling was linked to the pathogenesis of
these SCAs [36]. Their mutant proteins (Ataxin1, Ataxin2, Ataxin3,
b-III spectrin, CACNA1A, PKCg and ITPR1) affected calcium
signaling of Purkinje cells in the cerebellum, which could cause
Purkinje cells dysfunction and loss [36]. These studies suggested
that causative genes of FCMTE might share similar functions with
these SCAs genes described above in the role of calcium signaling
in Purkinje cells at the cerebellum.
In the cortical myoclonus (CM), a group of diseases that also
includes FCMTE and different types of progressive myoclonic
epilepsy (PME), the cerebellum has been widely suggested as
playing an important role in disease pathogenesis [37–39]. Ganos
et al. concluded that the cerebellum played a key role in motor
control and adaptation by its inhibitory function on the cortex
through the cerebello-thalamo-cortical loop where inhibitory
neurotransmission—GABA receptors play key roles [38,39]. This
indicated that genes associated with the GABA receptors might be
causative genes of FCMTE.
The above described studies on neuropathology suggest that
the causative genes of FCMTE might be linked to the SCAs (i.e.,
SCA1, 2, 3, 5, 14, 15 and 16) genes, calcium signaling in Purkinje
cells at the cerebellum and the GABA receptors.TE indicated some of the factors that might participate in the pathophysiology of
gical, and neuroimaging studies results of FCMTE. Frames after the arrows listed the
 damage of cerebellum, calcium signaling and GABA receptors. Abbreviations: PCs,
, downbeat positioning nystagmus; LD, Lafora disease; FA, fractional anisotropy.
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In 2012, clinical anticipation was reported in four Japanese
FCMTE pedigrees [40]. Clinical anticipation was usually observed
in diseases caused by trinucleotide repeats (or polynucleotide
repeats), for example in Dentatorubral–pallidoluysian atrophy
(DRPLA) and some types of SCAs. In 2013, the same group observed
clinical anticipation in all 12 FCMTE parent/child pairs (i.e.,
8 mother/child pairs and 4 father/child pairs) with regard to either
CMT or GTCS. A higher degree of clinical anticipation was
associated with maternal transmission [41]. These observations
suggested that trinucleotide repeat expansion (or polynucleotide
repeat expansion) should be considered in FCMTE.
In 2007, van Rootselaar et al. found that FCMTE patients
presented with signiﬁcantly reduced short-interval intracortical
inhibition (SICI), which indicated functional changes of the motor
cortex [32]. SICI was thought to occur through a GABAA-ergic
inhibitory postsynaptic potential [40]. In addition, the symptoms
in FCMTE diminished with clonazepam and valproic acid, which
were both GABA-ergic drugs [2]. These results further support the
notion that genes that are associated with GABA receptors might
be causative genes of FCMTE.
More interestingly, reduced SICI was also detected in patients
from four different German pedigrees with different mutations in
SCA14, which is a complicated form of SCAs that presents as
dystonia and myoclonus in addition to a slowly progressive
cerebellar ataxia [42]. Combining the neuropathology results of
the loss of Purkinje cells and abnormal Purkinje cells morpholo-
gy, and the reduced SICI, the cortical hyperexcitability might
be due to deﬁcient cerebellar Purkinje cells inhibition via the
cerebello-thalamo-cortical loop in both FCMTE and SCA14.
Eye movement recordings that showed downbeat positioning
nystagmus (DBN) and square wave jerks were also detected in
these FCMTE patients, which indicated cerebellar dysfunction
[32]. DBN was also detected in SCA6 patients, which shared
remarkable changes in neuropathological studies with FCMTE
[43].
The above discussed studies on the clinical and neurophysiolo-
gy suggest that dysfunction of the cerebellum was shared between
FCMTE and SCAs. In addition, the clinical anticipation in FCMTE
further supported common features between them, which
indicated that trinucleotide repeat expansion (or polynucleotide
repeat expansion) should be considered in FCMTE.
1.6. Updated studies on neuroimaging
In 2009, Striano et al. investigated the neurochemical patterns
in FCMTE2 patients with proton magnetic resonance spectroscopy
(1H-MRS). Elevated choline/creatine ratio (which indicated mild
neuronal loss with consequent gliosis) in the cerebellar cortex was
found. However, no difference in metabolite ratios in the frontal
and occipital cortex between patients and controls was found
[44]. In 2015, Long et al. also detected decreased N-acetylaspar-
tate/choline ratios, which reﬂected neuronal loss and secondary
astrocytosis in the cerebellar cortex [45]. These studies suggested
that the cerebellum was a prominent site of dysfunction in FCMTE.
Metabolic change in the cerebellar hemispheres was also reported
in patients with Lafora disease (another type of CM), which
indicated similar physiopathologic mechanisms between FCMTE
and Lafora disease.
In 2012, Buijink et al. compared cerebellar ﬁber density
between healthy controls, patients with FCMTE and essential
tremor (ET) by MR diffusion tensor imaging. They found a
signiﬁcantly decreased mean fractional anisotropy (FA) in FCMTE
patients that indicated microstructural damage of the cerebellar
white matter in FCMTE in vivo [46]. Cerebellar white matterdamage can potentially alter the cerebello-thalamo-cortical loop,
and thereby increase tonic facilitation of the motor cortex
[46]. These neuroimaging studies further supported that cerebel-
lum played an important role in FCMTE.
1.7. Future direction for causative gene identiﬁcation in FCMTE
Before NGS became the main tool for identiﬁcation of
causative genes in monogenic diseases, linkage analysis com-
bined with candidate gene sequencing was the classical strategy
for monogenic diseases causative gene identiﬁcation. Herein, we
reviewed previously reported studies on neuropathology, clinical
features, neurophysiology and neuroimaging in FCMTE. We
propose four conditions that candidate causative genes in the loci
of FCMTE may be associated with: (1) Genes encoding proteins
that are expressed in the cerebellum, especially in the cerebellar
cortex and Purkinje cells. (2) Genes encoding proteins that are
associated with calcium signaling. (3) Genes encoding proteins
that are associated with GABA receptors. (4) Genes that interact
with genes of speciﬁc SCAs (i.e., SCA1, 2, 3, 5, 6, 14, 15/16) and
some neurophysiologically proven or clinically suspected CM
(PME including Unverricht-Lundborg disease, MERRF, neuronal
ceroid lipofuscinosis, DRPLA, Gaucher disease, Lafora disease
and sialidosis). This information is not only helpful for the
selection of candidate causative genes in FCMTE, but it is also
useful in the identiﬁcation of causative genes and further
functional studies.
Although only reported by one group, clinical anticipation in
Japanese FCMTE pedigrees indicated trinucleotide repeat expan-
sion (or polynucleotide repeat expansion) might be the causative
mutation type of FCMTE [40]. Similar neuropathological, clinical,
neurophysiological and neuroimaging features shared between
FCMTE and SCAs also hint that there may be similar mechanisms
shared between them. The trinucleotide repeat expansion (or
polynucleotide repeat expansion) could be located in the coding
or non-coding regions. If the size of the expansion was large (i.e.,
approximately more than 80 bp for trinucleotide repeat expan-
sion or larger as is seen for large expansions of CGG in Fragile X
syndrome), NGS would not be suitable to detect it [47]. Other
special methods like Southern blot analysis could be used to
detect these mutations, if indeed there was a suspected candidate
gene.
Most NGS applications focus on the detection of SNVs or small
insertions/deletions (indels), which may miss some mutation
types like exon rearrangements, trinucleotide repeat expansion (or
polynucleotide repeat expansion) and CNVs. Recently, novel
algorithms of NGS were applied in the detection of these mutation
types [48–51]. These novel algorithms might offer further useful
information for the identiﬁcation of causative genes in FCMTE.
However, caution should be observed with regard these novel
algorithms since they still suffer from some limitations that might
miss some of these mutation types [47,52].
2. Conclusions
Combining the reports we have reviewed, we suggest that the
causative genes of FCMTE might be harboring a special type of
mutation which could not be detected by classical NGS
bioinformatics analysis. The encoding protein might be
expressed in the cerebellum, especially in the cerebellar cortex
and Purkinje cells, and might be associated with calcium
signaling and GABA receptors. The causative genes might also
interact with genes of some SCAs (i.e., SCA1, 2, 3, 5, 6, 14, 15/16)
and some neurophysiologically proven or clinically suspected
CM.
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